RxDoctor Payments Data

Dawn Martin

Optometrist · Mesa, AZNPI 1033115886

Payments from drug & device makers

$1,302in general payments, 2019–2025

Across 31 payments — averaging $42.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Notal Vision, Inc.$434
  • Bausch & Lomb Americas Inc.$419
  • AbbVie$130
  • Rxsight Inc$98
  • Aerie Pharmaceuticals, Inc.$60
  • Shire North American Group Inc$41
  • plus $120 from 5 others

What the payments were for

  • Speaking & faculty fees$43433%
  • Food & beverage$85165%
  • Gifts$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,302 in reported general payments places this provider in the 60th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$64,404
Medicare patients
357
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost91$50,283
XiidraLifitegrast21$25,587
RestasisCyclosporine14$17,581
Latanoprost1,048$15,728
Travoprost75$14,284
Timolol Maleate357$3,917
SimbrinzaBrinzolamide/Brimonidine Tart11$3,205
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$3,111
Levobunolol Hcl71$1,989
Brimonidine Tartrate93$1,444
Prednisolone Acetate19$1,239
Dorzolamide Hcl35$866
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat51$772
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha50$656
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$130$67,864105 claims
Bausch & Lomb Americas Inc.Xiidra$419$25,58721 claims
AlconSimbrinza$14$3,20511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →